Neurocrine Biosciences, Inc.

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
136.7 ^USD	-2.12%		-2.85%	+3.75%

May. 09	Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024	CI
May. 08	Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	CI

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

February 07, 2024 at 07:00 am EST

Neurocrine Biosciences, Inc. provided earnings guidance for the full year of 2024. For the year, company expects Net Product Sales of $2,100 million to $2,200 million.

Latest news about Neurocrine Biosciences, Inc.

Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024	May. 09	CI
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	May. 08	CI
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024	May. 07	CI
Neurocrine Biosciences Presents CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024	May. 03	CI
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating	May. 02	MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating	May. 02	MT
Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell	May. 01	MT
Transcript : Neurocrine Biosciences, Inc., Q1 2024 Earnings Call, May 01, 2024	May. 01
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q1 Revenue $515.3M, vs. Street Est of $512M	May. 01	MT
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Reports Q1 EPS $1.20, vs. Street Est of $1.29	May. 01	MT
Neurocrine Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024	May. 01	CI
Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours	Apr. 30	MT
Neurocrine Biosciences' Huntington's disease drug gets FDA approval	Apr. 30	RE
FDA approves Neurocrine Biosciences' Huntington's disease drug	Apr. 30	RE
Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules	Apr. 30	CI
Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170	Apr. 24	MT
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community	Apr. 24	CI
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder	Apr. 23	CI
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	Apr. 16	MT
Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development	Apr. 16	MT
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides	Apr. 16	CI
Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept	Apr. 08	MT
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study	Apr. 03	MT
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder	Apr. 03	CI

Chart Neurocrine Biosciences, Inc.

Duration

Period

More charts

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinsonâs disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinsonâs disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - BofA Securities Health Care Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Neurocrine Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

136.7 USD

Average target price

157.8 USD

Spread / Average Target

+15.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B
VIKING THERAPEUTICS, INC.	+295.70%	8.12B

Bio Therapeutic Drugs